People using Oregon’s state-regulated psilocybin services reported substantial improvements in symptoms of depression, anxiety and post-traumatic stress disorder during the first large multisite study of the program. The findings, published in JAMA Network Open, offer an early look at what happens when psychedelic services move beyond tightly controlled clinical trials and into a regulated, real-world setting. Nearly two-thirds of participants said their psilocybin experience ranked among the ten most meaningful events of their lives, while more than nine in ten said they benefited from the session one month later.
The study was led by researchers at Oregon Health & Science University and involved 346 adults who participated in a single psilocybin session with licensed facilitators at 24 service centers across Oregon. The sessions took place between November 2024 and June 2026, after Oregon’s voter-approved psilocybin services model became operational. Unlike a medical prescription system, Oregon’s framework is designed around supervised, non-medical wellness experiences for adults aged 21 and older. Clients do not need a specific psychiatric diagnosis to participate, although licensed facilitators must follow state rules governing preparation, administration and support during the psychedelic experience.
Participants completed web-based surveys before their session and again one week, one month and three months afterward. Approximately 90% continued providing information through the three-month follow-up, giving researchers an unusually detailed view of short-term outcomes in a commercial, state-regulated environment. The survey assessed symptoms associated with depression, anxiety and PTSD, along with broader measures of psychological wellbeing and life satisfaction. It also asked participants whether they considered the experience beneficial, meaningful or harmful and recorded adverse reactions requiring medical care.
At three months, participants reported lower levels of moderate-to-severe depression, anxiety and PTSD symptoms, as well as improved overall mental wellbeing and life satisfaction. The changes were reported even though only about half of the sample had moderate-to-severe depression symptoms at the beginning of the study. That distinction is important: most psychedelic clinical trials recruit people with clearly defined, clinically significant disorders, while Oregon’s regulated services attract a wider population seeking personal growth, emotional relief or general wellness. The results therefore do not establish psilocybin as a treatment for any particular condition, but they suggest that psychological benefits may also be reported by people outside traditional medical research populations.
The strongest responses involved participants’ interpretations of the experience. One month after their session, 91.5% said they had benefited, and 64.9% placed the experience among the ten most meaningful events of their lives. Such reports are consistent with a central feature of psychedelic research: psilocybin can produce an intense, temporary alteration in perception, emotion and the sense of self. In the brain, psilocybin is converted into psilocin, a compound that activates serotonin 2A receptors, particularly in cortical networks involved in perception, introspection and cognitive flexibility. Researchers believe this temporary disruption of habitual patterns may allow some people to reconsider distressing memories, beliefs or behaviors, especially when the experience occurs in a supportive environment.
Safety was a central question in the Oregon study because the state’s program differs from the highly controlled conditions of clinical trials. Researchers reported few harmful outcomes overall. Seven participants still considered the experience harmful three months later, and four people who were using psilocybin for the first time developed behavioral reactions serious enough to require medical attention. No participant reported a serious physical-health event related to psilocybin. The findings suggest that regulated supervision may reduce, but cannot eliminate, the risks associated with an unpredictable and powerful psychoactive substance.
The researchers emphasized that psilocybin is not appropriate for everyone. People with a history of psychosis or bipolar disorder may face elevated risks, and the substance is not recommended during pregnancy. Individuals with serious medical or psychiatric conditions should consult healthcare professionals before seeking psychedelic services. The Oregon model also depends heavily on screening, preparation and the behavior of facilitators, meaning that safety outcomes may vary between service centers. Because the study did not randomly assign people to psilocybin or a comparison group, it cannot determine whether the reported improvements were caused by the drug itself, participants’ expectations, the supportive setting, the passage of time or a combination of these factors.
That limitation is particularly important when interpreting the mental-health findings. Participants chose to seek psilocybin services and voluntarily enrolled in the research, which may have attracted people who were already motivated to change and more inclined to view the session positively. The surveys were self-reported rather than based primarily on diagnostic interviews conducted by independent clinicians. There was also no untreated control group, placebo group or comparison with conventional therapy. Consequently, the study measures associations between participation and later wellbeing rather than proving a direct therapeutic effect. Longer follow-up and controlled studies will be needed to determine how durable the changes are and which individuals are most likely to benefit or experience harm.
Oregon’s program has already provided psychedelic experiences to more than 20,000 people, according to Oregon Health Authority data, although cost remains a major barrier. A single supervised session can cost hundreds or thousands of dollars, placing access beyond the reach of many people who might seek help for depression, trauma or substance-use problems. Several Oregon counties have also chosen not to permit psilocybin service centers, partly because of concerns about public safety and the uncertain effects of expanding access. Researchers say the new data may help policymakers evaluate regulated psychedelic programs, but they also caution that favorable early results should not be mistaken for proof that commercial services can replace evidence-based mental-health care.
The study forms part of the Oregon Psychedelic Evaluation Nexis, or OPEN, a research initiative developed by OHSU, Legacy Research Institute and collaborating institutions to monitor outcomes in state-regulated psychedelic services. A five-year, $3.3 million federal grant will support further research on whether supervised psilocybin services influence the use of illicit substances. The researchers have also expanded the survey platform to Colorado, the second U.S. state to approve regulated psilocybin services, creating the possibility of comparing outcomes across different legal and operational environments. As psychedelic policy expands, systematic monitoring may provide the “apples-to-apples” evidence needed to distinguish genuine benefits from expectation, selection effects and hype. For now, the Oregon findings offer an unusually broad snapshot of psychedelic use outside the laboratory: promising reports of improved mental health and profound personal meaning, accompanied by a reminder that real-world access brings real-world risks.
Subject of Research: People
Article Title: Safety and Mental Health Outcomes of Oregon State-Regulated Psilocybin Services
News Publication Date: 19-Aug-2026
Web References: Oregon Psilocybin Services: https://www.oregon.gov/oha/ph/preventionwellness/pages/oregon-psilocybin-services.aspx; Oregon Psychedelic Evaluation Nexis: https://openpsychedelicscience.org/; Oregon Health Authority Psilocybin Data Dashboard: https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Pages/Psilocybin-Data-Dashboard.aspx; Healing Advocacy Fund: https://healingadvocacyfund.org/
References: JAMA Network Open, DOI: 10.1001/jamanetworkopen.2026.30608
Keywords: Psilocybin, psychedelic therapy, mental health, depression, anxiety, post-traumatic stress disorder, Oregon, psychedelic research, wellbeing, public health
